Skip to main content
SpringerLink
Log in

Rivaroxaban for PE reduces hospital stay and costs

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. 2015 US dollars

Reference

  • Margolis JM, et al. Pulmonary Embolism Inpatients Treated With Rivaroxaban Had Shorter Hospital Stays and Lower Costs Compared With Warfarin. Clinical Therapeutics : 14 Oct 2016. Available from: URL: http://doi.org/10.1016/j.clinthera.2016.09.007

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rivaroxaban for PE reduces hospital stay and costs. PharmacoEcon Outcomes News 765, 26 (2016). https://doi.org/10.1007/s40274-016-3511-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-016-3511-5

Search

Navigation